News

Better quality of life and greater functionality are the most important treatment goals for people with sarcoidosis, according to a large-scale survey of patient perspectives. Survey results are expected to be included in European Respiratory Society (ERS) guidelines to be released this year. They were reported in “…

Cash-strapped governments across the 28-member European Union are struggling to control runaway healthcare expenditures — at exactly the same time as the promise of new but expensive therapies to treat rare diseases has never been greater. That’s the paradox faced by pharmaceutical companies as well as patient advocacy groups in…

Treatment with Rituxan (rituximab) provided marked disease remission and was well-tolerated by three patients with refractory neurosarcoidosis, according to a new case report. The study, “Successful therapy with rituximab in three patients with probable neurosarcoidosis,” was published in the journal Therapeutic Advances in Neurological…

Adalimumab — marketed by (Abbvie) as Humira  — can help treat patients with verrucous sarcoidosis — a rare type of cutaneous (skin) sarcoidosis — associated with human papillomavirus (HPV) infection, according to a new case report. The study, “Chronic verrucous sarcoidosis associated with human papillomavirus infection:…

Cardiac arrhythmias are increasing among sarcoidosis patients, and they are linked with higher hospital admission and mortality rates, a U.S. patient population study finds. These results, published in the study, “The burden of cardiac arrhythmias in sarcoidosis: a population-based inpatient analysis,” highlight the need for timely diagnosis…